Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Senetek (SNTK) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (13)	11/4/2002 6:50:55 PM
From: SemiBull	Read Replies (1) \| Respond to of 101

Senetek PLC and The Body Shop Expand Kinetin Distribution to Europe and Asia Monday November 4, 7:05 am ET NAPA, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), ( www.senetekplc.com ), today announced the signing of an expansion of its license agreement with The Body Shop ( www.bodyshop.com ) under which The Body Shop will launch its Kinetin line of exclusively formulated skin care products in its retail stores, kiosks, catalogs and websites throughout Europe and Asia, beginning in the fourth quarter of this year. Frank J. Massino, Chairman and Chief Executive Officer of Senetek, said, "We are very pleased with The Body Shop's decision to go global with its Kinetin line which validates the success and effectiveness of Kinetin and the tremendous consumer loyalty that Kinetin products command. We expect that The Body Shop's global rollout will substantially increase unit sales of Kinetin and spread the word to consumers in markets where Kinetin is not presently represented." Caroline Hadfield, Director of Global Product, The Body Shop, said, "Our products incorporating Kinetin in the United States have been very popular with customers hence our decision to offer the range globally." Kinetin, Senetek's patented naturally occurring plant cytokinin, was developed at the University of Aarhus in Denmark and tested at the Department of Dermatology, University of California at Irvine, where it demonstrated good-to-excellent results in treating signs of photodamage and promoting the appearance of healthy skin. In clinical trials, Kinetin demonstrated improvement in the reduction of mottled hyperpigmentation and tactile skin roughness and was shown to increase moisture retention by helping to restore the skin's natural moisture barrier, all without the skin irritation often associated with retinol, alpha- and beta-hydroxy acids and other anti-aging skin care active ingredients. The Body Shop International PLC is a values driven, high quality skin and body care retailer operating in 50 countries with over 1,900 outlets spanning 25 languages and 12 time zones. Under the original license signed in May 2000, The Body Shop introduced Skin Re-leaf(TM) with Kinetin in North America and The Caribbean. Senetek PLC is a biopharmaceutical company focused on developing and co-marketing products in key skin care/dermatologicals and sexual dysfunction categories worldwide. Its patented Kinetin ingredient is currently licensed to some nine other companies with leading positions in their fields including Revlon and ICN Pharmaceuticals. Visit Senetek PLC's web site: senetekplc.com . Senetek PLC Investor Relations Contact: 1-707-226-3900 ext. 102 E-Mail: Pknopick@eandecommunications.com The Body Shop Corporate Public Relations Contact: Bill Eyres tel: + 44 (0) 1903 844040 Safe Harbor Statement: This news release may contain statements that may be considered "forward-looking statements" under the Federal securities laws, including statements concerning the revenue and licensing income the Company may receive in the future under licenses of the Company's products, and the additional licensing agreements the Company may enter into during 2002. No forward-looking statement the Company makes is a guarantee of future performance or events. Actual results or events may differ materially from those in the forward-looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended June 30, 2002, filed with the Securities and Exchange Commission. Make Your Opinion Count - Click Here -------------------------------------------------------------------------------- Source: Senetek PLC